Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
posted on
Jan 27, 2023 10:49AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
As I understand it, the trial was stopped because it failed to meet its endpoint (or wasn't expected to) not because of the adverse effects. I guess all trials inherently have adverse effects. Perhaps ZEN-3694 will put them over the line. Time will tell.
Koo (IMO)